Ralista 60 mg, which contains raloxifene, is sometimes used under medical supervision to help reduce the risk of hormone-related breast cancer in certain high-risk individuals. This is because some types of breast cancer grow in response to hormones—especially estrogen. When estrogen binds to receptors on breast cells, it can stimulate abnormal cell growth. Medications like raloxifene act as selective estrogen receptor modulators (SERMs), meaning they block estrogen’s effect in breast tissue while allowing it to act normally in other parts of the body.

Hormones play a major role in breast cancer because many tumors are hormone-receptor positive, meaning they depend on estrogen or progesterone to grow. Factors that increase lifetime hormone exposure—such as early menstruation, late menopause, hormone therapy, or certain genetic tendencies—can raise the risk. Understanding how hormones influence cancer development helps doctors choose the right treatments, such as hormone-blocking medications, targeted therapy, or lifestyle adjustments that reduce overall hormonal stimulation.